11:19:07 EST Mon 16 Nov 2026
Enter Symbol
or Name
USA
CA



Rubicon Organics Inc.
Symbol ROMJ
Shares Issued 68,889,479
Close 2026-11-13 C$ 0.425
Market Cap C$ 29,278,029
Recent Sedar+ Documents

ORIGINAL: Rubicon Organics Reports Q3 2026 Financial Results

2026-11-16 07:00 ET - News Release

  • Q3 2026 net revenue of $18.3 million and year-to-date net revenue of $50.4 million, both up 17% year-over-year.

  • Adjusted EBITDA1 of $1.4 million for Q3 2026, compared to $1.7 million in Q3 2025, as the Company continues to absorb the costs of scaling Cascadia.

  • Maintained position as the #1 premium licensed producer in Canada for Q3 2026 with 6.6% market share.2

  • Cultivation progress across both facilities, with Cascadia delivering quality that meets 1964 Supply Co™ brand standards and improving yields, alongside continued year-over-year yield improvements at Pacifica.

VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading licensed producer of premium cannabis products, announces it has reported its financial results for the three and nine months ended September 30, 2026. All financial information in this press release is reported in Canadian dollars, unless otherwise noted.

“2026 has been about building the platform for Rubicon’s next stage of growth, adding incremental supply from Pacifica and Cascadia, bringing key processes in-house and expanding our access to global markets." said CEO, Margaret Brodie.

"Demand for our premium products remains strong, and Cascadia is contributing meaningful revenue. While ramping the facility to optimal performance has taken longer than anticipated, results from recent crops reinforce our confidence in achieving targeted yields by year end. At Pacifica, yields have increased 16% year to date compared with the prior year, and successful lighting trials have demonstrated further opportunity to increase production. We have now moved to the next phase of this project, installing upgraded lighting across all of Pacifica’s cultivation areas, with two compartments operationalized to date. Our focus going forward is on translating this expanded platform into our financial results. With additional cultivation capacity, a growing international business and continued investment in genetics, we believe Rubicon is well positioned to deliver sustainable long-term growth.” she concluded.

“Q3 delivered solid net revenue growth and continued operating progress, with revenue of $18.3 million, up 17% year over year, and Adjusted EBITDA of $1.4 million. International sales represented 11.7% of quarterly net revenue as that program continued to ramp. And while margins continue to reflect the costs of scaling our expanded production platform, we are making strong progress on the initiatives expected to improve capacity, efficiency and financial performance as we move into 2027,” said Glen Ibbott, CFO.

Q3 2026 Highlights:

  • Net revenue increased 17% year-over-year to $18.3 million in Q3 2026 and increased 17% year-over-year to $50.4 million for the nine months ended September 30, 2026.

  • Adjusted EBITDA1 of $1.4 million for Q3 2026 (17% decrease from Q3 2025), an increase of 27% sequentially, even as Cascadia costs are included in our EBITDA calculation for the first time in Q3 2026.

  • Achieved a position in the top 10 among all licensed cannabis producers in the Canadian market for Q3 2026.2

  • Maintained position as the #1 premium licensed producer in Canada during Q3 2026 and for the nine months ended September 30, 2026.2
  • International markets program ramping up with 11.7% of Q3 2026 net revenue from global markets, and a successful launch of our 1964 Supply Co™ branded full spectrum vapes in the U.K. medical cannabis market, broadening the Company’s international product offerings.
  • Capacity and margin improvement projects continuing as planned:

    • Pacifica year to date cultivation yields increased approximately 16% year over year in 2026, with ongoing cultivation improvements and facility investments expected to support further growth and increase annual production capacity to approximately 15,500 kg in 2027.
    • Pre-roll production line fully automated as of August 2026.
    • Hydrocarbon extraction moving in-house, with facility installation and ramp-up underway through H1 2027 and commercial operations and related margin benefits expected in H2 2027.
  • Launched our first in-house developed genetic, BC Organic Caviar-Z, under the Simply Bare™ Organic brand.

  • Initial revenues of approximately $2.3 million from Cascadia facility realized in Q3 2026 ($2.7 million year to date).
  • Maintained #1 national market share of premium flower at 9.0% of the market in Q3 2026 and 9.7% year to date.2
  • Wildflower™ is the #2 topical brand in Canada with market share of 31.4% and #1 topical SKU in Canada.2  

  • 5.2% and 6.5% national market share of premium pre-rolls and vapes, respectively.2

Results of Operations

($000s) Three months ended  Nine months ended 
  September 30,  September 30, 
  2026 2025Variance 2026 2025Variance
Net revenue$18,260$15,62817%$50,400$42,98917%
Cost of sales  13,242 10,36728%  37,201 28,80829%
Gross profit before fair value adjustments  5,018  5,261(5%)  13,199  14,181(7%)
Fair value adjustments to cannabis plants, inventory sold, and other charges  123  2,777(96%)  3,025  3,963(24%)
Gross profit$5,141   $8,038(36%)$16,224 $18,144(11%)
             


As at: September 30, 2026 September 30, 2025
Cash and cash equivalents$4,235$6,685
Working capital$19,938$24,097
     

2026 Outlook

Leveraging Our New Scale

Demand for our premium-quality cannabis has consistently exceeded our available supply and increasing quality saleable production from our existing cultivation platform remains an important driver of future growth. The ramp-up of Cascadia has progressed more slowly than originally anticipated, with the facility currently approximately six months behind the Company’s initial production ramp expectations. Management remains confident in Cascadia’s production potential, supported by encouraging recent yield results, and continues to implement cultivation optimization initiatives, including improvements to genetics, lighting and growing practices, aimed at increasing yields toward targeted levels while maintaining premium product quality. Revenue contribution from Cascadia commenced late in Q2 2026 with Q3 representing the first full quarter of contribution and generating approximately $2.3 million, as the facility continues to scale production towards targeted levels.

At Pacifica, continued cultivation improvements and planned greenhouse upgrades are expected to further increase production from the facility. Year to date production at Pacifica has increased by approximately 16% year over year in 2026, with further growth expected as planned facility improvements are completed and annual production capacity increases to approximately 15,500 kg in 2027. Together with Cascadia, these investments are expected to increase the Company’s combined annualized cultivation capacity to approximately 20,000 kg by mid-2027, enhancing our ability to address demand across our domestic and growing international sales channels.

Cascadia obtained CUMCS and IMC-G.A.P. certifications, further supporting the Company’s ability to meet requirements of international medical cannabis markets and reinforcing its focus on quality and consistency across its cultivation platform. As we increase production across Pacifica and Cascadia, management remains focused on translating this additional supply into sustainable revenue growth and greater operating scale.

Continued Emphasis on Genetics

Our deep genetics library remains a core strategic differentiator. In 2026, we are focused on demonstrating the depth and consistency of that library. In Q3 we launched Pink Drip under 1964 Supply Co™ and BC Organic Velvet Octane and BC Organic Caviar-Z under Simply Bare™ Organic. The launch of BC Organic Caviar-Z represents the Company’s first in-house developed genetic coming to market, marking an important milestone and representing an exciting evolution of our genetics program. We believe a steady pipeline of sought-after cultivars is essential to maintain our leadership in the premium and super-premium segments of the Canadian market and drive long-term consumer loyalty.

Subsequent to Q3 2026, the Company received a micro-cultivation license for Arbora, which serves as our dedicated genetics facility in Squamish, British Columbia. Arbora expands our in-house genetics capabilities and provides a dedicated platform to support the development and evaluation of proprietary genetics. The facility is expected to strengthen our innovation pipeline and support a consistent introduction of differentiated cultivars across our premium and super-premium brands.

International

Building on the Company’s inaugural international shipments in 2025, we have continued to advance our international strategy throughout 2026. In April, the Company launched 1964 Supply Co™ in international markets with its first branded shipment of products to the U.K., marking the international introduction of the brand in a key market. During the third quarter, we further expanded our international presence with the launch of 1964 Supply Co™ vapes in the U.K. With four international revenue contracts now signed, the Company has expanded its pipeline of international sales opportunities and continues to build the presence of its premium brands in global markets.

Margin Improvements

During 2026, gross margins continue to reflect the transitional impact of scaling the Company’s production platform and investing in initiatives intended to support longer-term growth and profitability. This includes the ongoing ramp-up of Cascadia as yields progress toward targeted levels, as well as product mix and commercial initiatives designed to drive consumer demand and expand the Company’s market position.

Improving gross margin remains an important area of focus for management, supported by initiatives to increase cultivation yields, improve manufacturing efficiencies and ongoing optimization of the Company’s product portfolio. At Pacifica, year-to-date production has increased approximately 16% year over year, and the Company continues to invest in cultivation lighting and related greenhouse upgrades to further increase yields and lower per-unit cultivation costs. Following successful lighting trials, two compartments are now growing under the upgraded lighting, with additional fixtures on site with installation expected to be completed by the end of 2026. These investments, together with the continued ramp-up of Cascadia, are expected to increase the Company’s combined annualized cultivation capacity to approximately 20,000 kg by mid-2027, while lowering per-unit cultivation costs and improving gross margins as the benefits of increased scale are realized.

The Company is also investing in manufacturing efficiencies and bringing key processes in-house. During Q3 2026, the Company fully automated its pre-roll production with August representing the first month in which all pre-roll production was automated. Installation of the Company’s in-house hydrocarbon extraction facility is underway, with ramp-up and optimization planned through early 2027 and commercial operations and related margin benefits expected in the second half of 2027. As production volumes increase, cultivation and manufacturing efficiencies are realized and additional capabilities are brought in-house, management expects the benefits of these initiatives to become increasingly meaningful in 2027.

Financial Growth

The Company expects continued revenue growth through the remainder of 2026 and for the full year 2027 to be supported by strong demand across its domestic and international sales channels and increasing production from its expanded cultivation platform. Cascadia continues to progress toward targeted yield levels, with recent results providing increased confidence in the facility’s production potential, while investments at Pacifica are expected to expand the Company’s available supply as their benefits are realized.

With demand expected to absorb additional production, management remains focused on translating increased supply and scale into improved financial performance. We expect the benefits of the investments made across our operating platform to become increasingly meaningful in 2027 and believe our expanded cultivation capacity and growing sales channels position the Company to continue the current growth trajectory.

Q3 2026 Conference Call

The Company will be hosting a conference call to discuss the results on Monday, November 16, 2026. Conference call details are as follows:

Time:8:00 AM PCT / 10:00 AM EST
Conference ID:45311
Local dial-in: (+1) 289 514 5100
Toll Free N. America:(+1) 800 717 1738
Webcast:https://onlinexperiences.com/Launch/QReg/ShowUUID=CEB4A826-A47C-465A-BCF9-EE215FEF43CB
  

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is a Canadian leader in certified organic and premium cannabis, with a portfolio of trusted brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates the 125,000-square-foot Pacifica hybrid greenhouse in Delta, British Columbia, and the 47,500-square-foot Cascadia indoor facility in Hope, British Columbia, with current annual production capacity of approximately 15,500 kilograms of premium cannabis, expanding to 20,000 kilograms by mid 2027. Rubicon’s proprietary genetics, award-winning products and international certifications support its growth in Canada and regulated international markets.

For more information visit www.rubiconorganics.com. 

CONTACT INFORMATION

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Non-GAAP Financial Measures

This press release contains certain financial performance measures that are not recognized or defined under IFRS (“Non-GAAP Measures”) including, but not limited to, “Adjusted EBITDA”. As a result, this data may not be comparable to data presented by other companies.

The Company believes that these Non-GAAP Measures are useful indicators of operating performance and are specifically used by management to assess the financial and operational performance of the Company as well as its liquidity. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. For more information, please refer to the “Selected Financial Information” section in the MD&A for the year ended December 31, 2025, which is available on SEDAR+ at www.sedarplus.ca.

Adjusted EBITDA

Below is the Company’s quantitative reconciliation of Adjusted EBITDA calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes, and pre-revenue startup costs. The following table presents the Company’s reconciliation of Adjusted EBITDA to the most comparable IFRS financial measure for the three months ended September 30, 2026 and 2025.

($000s) Three months ended 
  September 30, 
  2026  2025 Variance
Income (loss) from operations$ 172  $3,009 (94%)
IFRS fair value accounting related to cannabis plants and inventory  (123) (2,777)(96%)
Depreciation and amortization  1,169   793 47%
Share-based compensation expense  217   462 (53%)
Cascadia pre-revenue startup costs* —     252 (100%)
Adjusted EBITDA$1,435 $1,739 (17%)
*Consistent with industry practice, beginning in Q3 2025 the Company has adjusted Cascadia Facility pre-revenue startup costs from Adjusted EBITDA to show a comparable and consistent operating performance measure. Beginning in Q3 2026, these costs are no longer excluded, as the facility began generating revenue in Q2 2026.
 

Cautionary Statement Regarding Forward Looking Information

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements other than statements of historical fact are forward-looking statements and are often, but not always, identified by words such as "expects", "anticipates", "believes", "plans", "intends", "estimates", "targets", "potential", "positioned", "will", "may", "would", "could" or "should", or variations of such words and phrases. Forward-looking statements in this press release include, but are not limited to, statements regarding: demand for the Company's products relative to available supply; Cascadia's progress toward targeted production levels and continued yield improvements; expected production growth at Pacifica, including annual production capacity of approximately 15,500 kg in 2027; combined annualized cultivation capacity of approximately 20,000 kg by mid-2027; the expected timing and benefits of planned lighting and greenhouse upgrades at Pacifica; the planned commencement of in-house hydrocarbon extraction in early 2027; expected improvements in gross margin and per-unit cultivation costs; the expected benefits of the Arbora genetics facility and the Company's genetics pipeline; the expansion of the Company's international business, including future sales under new international revenue contracts; and the Company's expectations for continued growth and improved financial performance in 2027 and beyond.

Forward-looking statements are based on assumptions and estimates that management considers reasonable as of the date of this press release, including, among other things: continued demand for the Company's products at expected pricing; the Company's ability to achieve anticipated cultivation yields and product quality at Cascadia and Pacifica; the completion of planned facility upgrades and in-house extraction capabilities on expected timelines and budgets; the receipt and maintenance of required licenses, permits and certifications, including those needed for international sales; the performance of counterparties under the Company's sales agreements; a stable regulatory, tax and excise duty environment; the availability of financing on acceptable terms, if required; and the Company's ability to execute its strategic initiatives.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These include, among others: the risk that anticipated production, yield, capacity, operational efficiency, revenue, margin or profitability levels are not achieved, or not achieved within expected timeframes; delays, cost overruns or other difficulties in completing planned facility upgrades or commencing in-house extraction; crop loss, pests, disease and other cultivation risks; changes in market conditions, consumer preferences, pricing and competition; risks related to international expansion, including foreign regulatory requirements, export and import permits and counterparty performance; changes in laws, regulations and excise duties; the Company's liquidity and access to capital; and other risk factors described in the Company’s public disclosure filings available on SEDAR+ at www.sedarplus.ca. 

Readers are cautioned not to place undue reliance on such forward-looking information. Although the Company has attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information.

All forward-looking information in this press release is made as of the date hereof and is based on the beliefs, estimates, and opinions of management as of the date such statements are made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable law.

1Adjusted EBITDA is a non-GAAP measure that is calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, fair value changes, and pre-revenue startup costs. See Non-GAAP Financial Measures for details on the Adjusted EBITDA calculation.
2Hifyre data for the three and ninemonths ended September 30, 2026 and September 30, 2025.


Primary Logo

© 2026 Canjex Publishing Ltd. All rights reserved.